ABBOTT INDIA - a Technical and Fundamental study

is currently navigating a pivotal technical juncture, trading in the ₹26,100 to ₹26,435 range after testing a long-term ascending support line near the ₹25,955 level shown on the chart. This multi-year trendline, originating from the early 2020 lows, has consistently acted as dynamic support and validates the stock's structural secular bull market. Trading volume has tapered during the recent pullback, suggesting a phase of healthy consolidation rather than aggressive distribution. If the stock maintains its footing above this critical upward trajectory, the technical setup strongly favors a resumption of the primary uptrend toward previous highs. However, a decisive breakdown below this support line on expanding volume would invalidate the bullish structure and signal a macro trend shift. The company exhibits a formidable fundamental profile that justifies its long-term technical appreciation. Valuation and operational metrics highlight its position as a premium growth asset in the pharmaceutical sector: Its most recent Q1 FY2026-2027 results demonstrate continued operational excellence. Net profits surged 17.13% year-over-year to ₹428.52 Cr. Revenue for the same period expanded by 4.3% year-over-year to reach ₹1,889.05 Cr. While the P/E multiple of 34.71 represents a premium valuation, it is strongly supported by the company's expanding net profit margins, which recently climbed to 22.68%.